Cord blood (CB) units are increasingly used for allogeneic transplantation. Cell dose, a major factor for CB selection, is evaluated before freezing by each CB bank, using various techniques. This may introduce variability and affect the prediction of cell recovery after thawing, or haematopoietic reconstitution. Forty-two children were transplanted at the same institution with unrelated CB units. All units were thawed and evaluated at the same cell therapy facility, using standard procedures. We investigated: (i) factors that affect cell loss after thawing, and (ii) the importance of CD34 þ cell doses. Prefreeze and postthaw CD34 þ cell doses were statistically correlated, thus suggesting that variability in numeration techniques used by different CB banks does not compromise the biological and clinical value of these figures. CD34
Introduction
The use of allogeneic haematopoietic stem cell (HSC) transplantation is limited by the risk of graft-versus-host disease (GVHD) and the lack of identical sibling donors. Bone marrow (BM) or peripheral blood (PB) mobilized progenitor transplantation from an unrelated donor produce acceptable results when donor and recipient are 9/10 or 10/10 HLA-matched. 1, 2 The search for a donor is thus far from being systematically successful, and may require several weeks. 3 By contrast, access to banked cord blood (CB) units is faster, and CB transplantation outcome was shown to be less influenced by HLA disparities. Despite lower number of HSC and progenitor cells in CB units compared with adult HSC sources, CB cells have higher proliferative capacities and their immunological immaturity [4] [5] [6] allows HLA-mismatched transplantation, with reduced frequency and severity of GVHD. [7] [8] [9] [10] [11] [12] [13] Nevertheless, cell dose is a major limitation for CB transplantation. The total nucleated cell (TNC) number is a primary determinant for CB selection by transplant teams as it correlates with time and probability of engraftment and overall survival. 12, [14] [15] [16] Engraftment is known to be slower than that observed with BM or mobilized PB transplantation, 7, 17, 18 owing to a log less TNC and CD34 þ cell doses and to immaturity of HSC. In addition, the use of CB rather than BM or blood cells introduces another step in graft processing and cause for cell loss: the variability of TNC or CD34 þ cell recovery after thawing inevitably leads to the transplantation of a lower than cryopreserved number of cells. It is important to assess to what extent the variability in cell numeration techniques utilized by CB banks and transplant centres may affect the evaluation of cell loss. Two recent studies reported an important inter-laboratory variability of CD34 þ cell counts measured by flow cytometry, 19, 20 which could be attributed to the staining method 19 or to the instrument settings. 20 These technical issues do not affect the intrinsic quality of the CB graft, but can ultimately influence the decision of clinical investigators to select a CB unit. Another factor that may explain variability of cell recovery is the influence of subsequent processing steps (either before freezing or after thawing), which could affect CB quality.
To evaluate parameters that influence cell loss after thawing, and to more precisely define which of the frozen or infused cell doses better predict the kinetics of haematopoietic engraftment, we retrospectively analyzed our single centre experience of CB transplantations.
Patients and methods

Patients
Fifty-three consecutive children were transplanted with unrelated CB at the same institution, between January 1998 and December 2004. Excluding from the analysis second allogeneic transplantations and CB banks that provided less than 4 CB units, we analysed 42 unrelated single CB transplantations (Table 1) .
Patients were treated for non-malignant diseases (n ¼ 9), or malignant diseases (n ¼ 33) either in complete remission (n ¼ 28) or in relapse (n ¼ 5) (Table 1) . Children received a myeloablative-conditioning regimen using total-body irradiation (12 gy in 3 days and six fractions with lung shielding at 8 gy) and cyclophosphamide for 28 of them or busulfan and cyclophosphamide for the 14 others. In all cases, antithymocyte globulin (rabbit ATG, Thymoglobine) was infused at a dose of 2.5 mg/kg/day from day À3 to À1. Etoposide was added in seven children considered at high risk for post-transplant leukemia relapse. All patients received cyclosporine A and steroid for GVHD prophylaxis.
Haematopoietic reconstitution was defined as the number of days from transplantation to a neutrophil count 40.5 Â 10 9 /l and a platelet count 420 and 50 Â 10 9 /l without transfusion.
Outcome was evaluated in September 2006, that is 2 years after the last transplantation.
Frozen cord blood units CB units were obtained from six CB banks: Du¨sseldorf (n ¼ 5), Milano (n ¼ 4), London (n ¼ 6) and the French CB Bank Network, Re´seau Franc¸ais du Sang Placentaire (n ¼ 27) (Paris, n ¼ 8; Besanc¸on; n ¼ 14, and Bordeaux, n ¼ 5).
HLA-typing was systematically confirmed in our center by A and B low resolution molecular typing and DRB1 high-resolution molecular typing. There were from 1 to 3 HLA disparities between the patient and the CB (Table 1) .
Cell counting methods and freezing techniques were specific to each CB bank. Results are shown in Table 2 . Seven of the 42 CB had been volume reduced before freezing.
With the exception of five cases, selection of CB units was based on initial published consensus: 11 selected CB units contained more than 3.7 Â 10 7 TNC/kg before cryopreservation (with exception of the two patients, transplanted with a CB unit which contained 3.2 and 1.8 Â 10
7 TNC/kg before cryopreservation), with 0-2 HLA mismatches (with exception of three patients, transplanted with a three HLA-mismatched CB unit).
Thawing procedures
All CB units were thawed and washed at the same cell therapy facility, using a single procedure, based upon the technique initially described by Rubinstein et al. 21 Briefly, CB units were thawed in a 38-401C water bath. The thawed unit was immediately diluted with 2 volumes of cold dextran (Dextran 40; Fresenius Kabi, France) and centrifuged at 400 g for 15 min at 41C, and excess supernatant was carefully removed. The pellet was diluted in cold 4% human serum albumin (HSA) solution (Laboratoire Franc¸ais du Fractionnement et des Biotechnologies, Courtaboeuf, France). (Table 3) .
Quality controls on thawed CB Immediately after thawing, samples were systematically collected and analysed from final cell products before infusion. TNC count was first done using an hematology analyser (Coulter AcT, Beckman-Coulter). Samples were then diluted to 20-30 Â 10 6 cells/ml by addition of a phosphate-buffered saline (PBS) solution, supplemented with 0.5% human immunoglobulin. Absolute counts of CD34 þ and CD45 þ cells were determined using the StemKit numeration kit (Beckman-Coulter). This commercially available diagnostic kit includes the viability dye 7-amino actinomycin D (7-AAD), that allows for a quantitation of viable CD34
þ and CD45 þ cells.
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Absolute lymphocyte counts were determined using the Multitest kit (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). This commercially available diagnostic kit allows for a quantitation of
Data acquisitions and analyses were performed on a FACSCalibur four-color flow cytometer using the Cellquest and Multiset softwares (Becton Dickinson Immunocytometry System, BDIS, San Jose, CA, USA). Stem kit data were analysed following the ISHAGE protocol.
Cell recoveries were computed from values produced by each bank before freezing, and values measured in our laboratory after thawing (Table 2) .
Statistical analyses
Data were summarized by frequency and percentage for categorical variables. Furthermore, the median and range were computed for continuous variables.
To investigate the association between continuous variables and categorical variables, univariate statistical analyses were performed, using non-parametric Wilcoxon rank sum test or Kruskal-Wallis rank sum test.
For cell doses before freezing and after thawing, continuous data were transformed into binary variables using the estimate of the sample quartiles. The comparisons between two groups of CB were carried out using a MannWhitney test.
The Spearman's-r statistic test was used to estimate a rank-based measure of association between two continuous variables. We tested whether the correlation value was zero using a Spearman's test.
To study more precisely correlations between cell doses and haematopoietic recovery, a quartile comparison was done, using a Mann-Whitney test. All survival times were calculated from the date of transplantation. Overall survival rates were estimated by the Kaplan-Meier method. The logrank test was performed to compare groups. Cox's proportional hazards regression was applied to investigate overall survival in multivariate analysis. All statistical tests were two-sided and a P-value of less than 0.05 was considered statistically significant. Statistical analyses were performed using the R2.2.1 software (R Development Core Team).
Results
CB cell recovery after thawing
Since July 2003, dextran has been replaced with Voluven, because dextran was no longer available in France. This change in the thawing step was first validated in a preclinical comparison made on disqualified CB from our own CB Bank. We first evaluated the possibility to replace dextran by Voluven (n ¼ 2; CD34 þ cell recoveries were 4100% in both cases). Then, on disqualified CB units frozen in two separate bags, we compared CD34 þ cell recovery at thawing when using dextran to thaw one bag and Voluven to thaw the other one (n ¼ 3; CD34 þ cell recoveries were 88/82, 50/75 and 89/92%, respectively). This preclinical study could not be extended, because dextran was no longer available. Based on these encouraging preclinical results, we replaced dextran by Voluven for the clinical use; preclinical results were confirmed by the retrospective analysis of the 42 transplantations. We did not find any statistical difference in term of cell recoveries when replacing dextran by Voluven for the thawing step (Table 3) .
After thawing the 42 CB for transplantation, the median TNC dose was 5.3 Â 10 7 /kg, with median cell viability at 71%. The median dose of viable CD34 þ cells was 1.4 Â 10 5 /kg. Median recoveries were 78% for TNC and 60% for viable CD34 þ cells (Table 2) . Despite the various techniques utilized by each CB bank to measure CD34 þ cell counts on fresh CB, CD34 þ cell doses before freezing and after thawing were highly correlated ( Figure 1a 
þ cell recoveries after thawing. In particular, although a recent study on CB volume reduction 24 found a possible effect of CB hematocrit on clonogenic assays before freezing, we did not find any influence of the frozen CB hematocrit on cell recovery or viability after thawing. As we did not find any influence of erythroblast counts, subsequent analyses of nucleated cells counts used the most common TNC counts (including erythroblasts).
The negative influence of a high CD34 þ cell number on CD34
þ recovery prompted us to compare post-thaw recoveries between volume-reduced (n ¼ 7) and nonvolume-reduced (n ¼ 35) CB units. We did not find any statistical difference between these two freezing techniques for the investigated parameters (frozen CD34 þ or TNC counts number or concentration of CD34 þ cells per bag, number of neutrophils, or hematocrit per frozen bag; viability at thawing, thawed viable CD34 þ cells, TNC and CD34 þ recoveries).
Haematopoietic reconstitution
We did not find any difference in haematopoietic reconstitution delays between volume-reduced (n ¼ 7) and non-volume-reduced (n ¼ 35) CB units. Neutrophil reconstitution at 0.5 Â 10 9 /l occurred at a median of 31 days (range: 14-81 days). The first transplanted patient -treated for non-Hodgkin's lymphoma and for whom the selected CB contained 1.8 Â 10 7 frozen TNC/kg (1.2 infused TNC/kg) -reached a neutrophil count 40.5 Â 10 9 /l at day 55, and is still in complete remission as of today (100 months after transplantation). Two patients (4.8%) died of relapse before neutrophil recovery. Platelet reconstitution at 20 and 50 Â 10 9 /l occurred at a median of 53 and 65 days, respectively (ranges: 18-210, and 24-232 days, respectively). Eight patients (19%) died before full platelet reconstitution evaluation (four relapses, two infections, one rejection and one acute GVHD). Except for a positive relationship between the age at transplantation and the delay of platelet reconstitution at 50 Â 10 9 /l (P ¼ 0.03), an observation consistent with a previous report, 25 no other correlation was found between haematopoietic recoveries and patient characteristics at transplantation (weight, diagnosis and HLA mismatch).
Several correlations were found between the kinetics of haematopoietic reconstitution and cell doses, measured either before freezing or after thawing (Table 4) . Although the number of CD34 þ cells before cryopreservation did not correlate with neutrophil or platelet recovery, the number of infused CD34 þ cells was highly correlated with platelet recovery (Po0.05). Correlations were graduated, comparing Spearman's correlation coefficient-r. Infused TNC seems to better correlate with neutrophil recovery than frozen TNC (Spearman's-r ¼ À0.373 vs À0.339). The cell dose that better correlated with platelet reconstitution delays was infused CD34 þ cell dose, either to reach 20 or 50 Â 10 9 platelet/l (Spearman's-r ¼ À0.484 and -0.567, respectively). Interestingly, infused CD3 þ 8 þ better correlated with platelet recovery than infused TNC, especially for platelet 450 Â 10 9 /l (Spearman's-r ¼ À0.5 vs À0.42). The relationship between the kinetics of haematopoietic reconstitution and CD34 þ cell doses/kg, was also evaluated with quartile comparisons on patients who did engraft (Figure 2 ). For each of the comparisons, a cutoff was defined that divided the population in two statistically different subgroups in terms of neutrophil or platelet kinetics of engraftment. Neutrophil reconstitution delay was shorter for patients receiving CB units that contained either X4.775 Â 10 /l in a shorter delay; this analysis did not allow us to define a cut-off for frozen CD34 þ cell doses that could affect platelet reconstitution delay.
Overall survival
Overall survival (Figure 3) was evaluated for all patients in September 2006 (2 years after the last transplantation). At this time, the median follow-up of alive patients was 58 months (range (21-102) ). Twenty-three patients were alive in complete remission. One patient had recently relapsed at the time of the evaluation. Eighteen patients had died from 1 to 13 months after transplantation, with a death occurring at a median of 3 months. Half of them died of relapse, and half of transplant related mortality (five infections, one rejection, one acute GVHD, one chronic GVHD and one organ failure). Overall survival probability was 57% at 36 months (IC 95 (44-74) ). In a multivariate analysis, the only factor correlated with overall survival was diagnosis (P ¼ 1.7 Â 10 À6 ); no correlation was found with CB cell doses or other patient characteristics (age and 
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þ cells in CB transplantation C Lemarie et al weight at transplantation, HLA mismatch). Finally, we did not find any difference in overall survival between volumereduced (n ¼ 7) and non-volume-reduced (n ¼ 35) CB units.
Discussion
Umbilical CB represents a stem cell source for almost every child or adult in need of an unrelated transplantation, with a probability of survival similar to that obtained with unrelated BM transplantation, at least in children. 7 As clinical outcome is known to be affected by the transplant centre experience, 16 we took advantage of our single-centre experience to eliminate this so-called 'centre effect'. In addition, we focused on six CB banks that provided 4 CB units or more, testifying to experience.
The first aim of our retrospective analysis was to investigate parameters, which could influence cell loss after thawing. We first verified that changing the thawing solution did not influence cell recoveries. Then we investigated whether variations in cell counting techniques affected the correlation between values measured before and after cryopreservation. Concerning CD34 þ cell counts, our data demonstrate the existence of a high correlation between prefreeze and post thaw values respectively produced by CB banks and our transplant center. These observations suggest the CB unit selection criteria should include CD34 þ cell counts despite the variability induced by multiple techniques used for cell numeration in CB banks. In contrast to previously published studies, 26, 27 we observed a significant correlation prefreeze/post-thaw by the use of a single cytometry platform for the quality control step. As suggested in preliminary studies about CD34 þ cell measurement 19, 20 and CB thawing, 28 our results confirm, under transplantation conditions, that standardization of CD34 þ cell numeration techniques and use of single platform cytometry are necessary to better estimate the CD34 þ cell influence in CB transplantation. Concerning TNC counts, frozen and infused TNC doses also correlated, as well as TNC and CD34 þ cell doses either before freezing and after thawing. Exclusion of erythroblasts from the TNC count before freezing does not abolish the correlation between nucleated and CD34 þ cell counts. This observation is consistent with previous studies showing that inclusion of erythroblasts in TNC count does not reduce the usefulness of TNC count to predict engraftment speed. 29 We also analysed the influence of various factors on cell recovery at thawing. The only factor correlated with CD34 þ cell recovery after thawing was the absolute number of CD34 þ cells in the frozen cell product. This was not a consequence of CB volume reduction, as the inclusion of this step in precryopreservation processing did not affect cell recovery after thawing. Our study is thus consistent with a previous report comparing TNC recovery of un-manipulated vs volume-reduced CB, 30 and provides additional information regarding the recovery of CD34 þ cells: most published studies evaluated cell recovery of the volume reduction step itself; 24, 31 some measured TNC recovery after thawing, 32 but none compared CD34 þ cell recovery at thawing of volume reduced vs unmanipulated cord blood. Expectedly, we did not find any difference in terms of haematopoietic recovery between patients transplanted with volume reduced CB and patients transplanted with unmanipulated CB, similarly to what was reported in several multicentric studies comparing the clinical outcome of adult and paediatric patients transplanted with volume-reduced CB vs un-manipulated CB. 33, 34 However, as volume-reduced CB are increasingly banked, a larger monocentric study of an homogeneous population of patients will be helpful to better establish the influence or not of volume reduction, and broadly of CD34 þ absolute number, on CD34 þ cell recovery and clinical outcome after CB transplantation.
The other aim of our study was to determine whether CB cell subsets -measured either before cryopreservation or after thawing and washing -influence haematopoietic reconstitution. We first compared the influence of each cell dose on neutrophil or platelet recovery. The statistical tests used do not allow study of the influence of cell doses on haematopoietic recovery using an univariate analysis (Spearman's correlation test), and this kind of comparison of numerical data does not allow us to perform a multivariate analysis. So to more precisely study correlations between cell doses and haematopoietic recovery, a quartile comparison was done, using a Mann-Whitney test. The prefreeze TNC dose is clearly associated with transplantation end points, especially engraftment kinetics, 16 and is routinely used for CB selection. Post-thaw TNC counts seem to be better correlated with neutrophil reconstitution delay than frozen TNC; however, the difference between the two correlation coefficients is not powerful enough to draw firm conclusions. The usefulness of progenitor numbers to predict haematopoietic recovery is controversial. 11, 25, 33 It is important to stress that our observations were made in a population of patients who received CB units that were selected based on a high TNC content (43.7 Â 10 7 TNC/kg, median: 7.2 Â 10 7 TNC/kg), 
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þ cells in CB transplantation C Lemarie et al whereas the previously reported experience 25 analysed transplantations with CB units that contained a median TNC number of 3.1 Â 10 7 TNC/kg. We could not analyse clonogenic assay results because of the small number of exploitable results. Using Spearman's correlation tests, it appears that the infused CD34 þ cell dose was the cell dose that better correlated with platelet reconstitution delays but neither frozen nor infused CD34 þ cell doses were correlated with neutrophil recovery. Further, when excluding individuals who failed to engraft for various reasons, and using comparison of quartile patient populations, it appears that CD34 þ cell counts, both frozen and infused, were associated with neutrophil and platelet reconstitution delays. Our results complete previous reported experience showing a correlation between injected CD34 þ cell dose and probability of engraftment. 25 The different threshold values for cryopreserved and thawed CD34 þ cell numbers, reflect the fact that values were computed from slightly different patient subsets, as CD34 þ cell numbers were not available for all patients before and after cryopreservation. Because there is a relationship between CD34 þ cell content and TNC content, this means that we examined the relation between infused cell doses and haematopoietic recovery over a restricted range of values for potentially causative parameters.
Interestingly, we observed a strong correlation between the CD3 subpopulation cell doses, mainly the CD3 þ / CD8 þ cells, and platelet reconstitution. However, our results have to be interpreted carefully as we found a statistically significant relationship between CD3 þ /CD8 þ and CD34 þ absolute cell numbers, the later being the most predictive factor for platelet reconstitution. We also observed a statistical link between the CD3 þ /CD8 þ and TNC counts, whereas we did not find any influence of the CD3 subpopulations cell doses on neutrophil reconstitution. Therefore, the role of an accessory cell population to be defined, which should influence the haematopoietic reconstitution, has to be further investigated.
In conclusion, our single transplant centre experience provides evidence that variability in biological techniques used for cell counting does not eliminate correlation between values estimated before and after cryopreservation. Also, in addition of being dependent on the cryopreserved and infused TNC dose, platelet and neutrophil reconstitution are dependent on CD34 þ cell doses. Finally, correlations between haematopoietic recoveries and cell doses were stronger with infused cell doses than with frozen ones. Taken together, our data support the hypothesis that prefreeze CD34 þ cell dose should complete CB unit selection based on TNC doses, whereas CD34 þ infused cell dose may be an additional and useful parameter to predict engraftment kinetics and make appropriate clinical decisions.
